A detailed history of Two Sigma Securities, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Securities, LLC holds 13,941 shares of LCTX stock, worth $6,970. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,941
Holding current value
$6,970
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.8 - $1.12 $11,152 - $15,613
13,941 New
13,941 $12,000
Q4 2023

Feb 14, 2024

BUY
$0.91 - $1.35 $11,560 - $17,150
12,704 New
12,704 $13,000
Q1 2023

May 15, 2023

SELL
$1.2 - $1.53 $938 - $1,196
-782 Reduced 4.52%
16,538 $24,000
Q4 2022

Feb 14, 2023

BUY
$1.02 - $1.5 $17,666 - $25,980
17,320 New
17,320 $20,000
Q4 2021

Feb 14, 2022

SELL
$1.84 - $2.68 $178,042 - $259,322
-96,762 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$2.26 - $2.86 $218,682 - $276,739
96,762 New
96,762 $244,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $84.9M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Two Sigma Securities, LLC Portfolio

Follow Two Sigma Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Securities, LLC with notifications on news.